Japan's financial giant Nomura Holdings is scaling back risk at its digital asset unit following Q3 losses, a strategic pullback that mirrors wider pain across the crypto treasury sector as Bitcoin struggles to hold key levels.
The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for safety. We analyze one steady performer with durable advantages and two companies where challenges may outweigh the stability premium.
As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
Despite outperforming key benchmarks, APA Corporation faces a wall of analyst skepticism. With shares already trading above the average price target, the energy producer's disciplined strategy collides with muted expectations for near-term gains.
While trading near 52-week highs can signal strength, it can also precede a correction. We examine three stocks where current valuations may not justify the price tag, urging investors to look beyond the hype.
While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.
While strong cash generation is a hallmark of a healthy business, it's not the whole story. We analyze three companies with solid cash flow, highlighting one that reinvests for growth and two where underlying risks may outweigh the financial metrics.
In the quarters leading to his retirement as CEO, Warren Buffett orchestrated a significant portfolio shift, slashing Berkshire's stake in Bank of America while steadily accumulating shares in Domino's Pizza, highlighting a strategic bet on consumer resilience and brand loyalty.
Havana denies White House accusations of being a security threat while appealing for constructive talks, as U.S. pressure cuts off vital Venezuelan oil supplies and risks a humanitarian crisis.
U.S. energy firm BKV has completed a $115.1 million transaction to raise its stake in the BKV-BPP Power joint venture to 75%, gaining operational control as it positions to meet surging electricity needs from Texas's booming data center and AI sector.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
A final arbitration ruling in favor of Venture Global LNG against Spain's Repsol resolves a high-stakes contractual dispute, providing clarity on cash flows and bolstering confidence in the company's long-term project viability amid volatile energy markets.
Mitsubishi UFJ Financial Group's shares have surged nearly 50% in the past year, capping a remarkable five-year run. As the stock trades near ¥2,751, investors are divided: does the valuation still offer a margin of safety, or has the rally run its course? We delve into the metrics and market sentiment.
While geopolitical tensions have rattled regional markets, a closer look reveals resilient smaller companies in the GCC and Turkey offering unique value propositions. We analyze three firms with market caps under $900 million in the education, packaging, and industrial sectors.
In a landmark deal reshaping the U.S. energy landscape, NRG Energy has completed its acquisition of LS Power's 13GW natural gas fleet and virtual power plant platform, significantly boosting its capacity and demand-response capabilities in key markets.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
